New England Journal of Medicine最新文献

筛选
英文 中文
More on Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies. Reply. 更多关于腺病毒相关血小板减少症、血栓形成和VITT样抗体的信息。回复
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 DOI: 10.1056/NEJMc2310644
Theodore E Warkentin, Jacquelyn Baskin-Miller, Stephan Moll
{"title":"More on Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies. Reply.","authors":"Theodore E Warkentin, Jacquelyn Baskin-Miller, Stephan Moll","doi":"10.1056/NEJMc2310644","DOIUrl":"10.1056/NEJMc2310644","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"389 18","pages":"1729-1731"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. 杜伐单抗治疗癌症的围手术期。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 Epub Date: 2023-10-23 DOI: 10.1056/NEJMoa2304875
John V Heymach, David Harpole, Tetsuya Mitsudomi, Janis M Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T Le, Mike Aperghis, Gary J Doherty, Helen Mann, Tamer M Fouad, Martin Reck
{"title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.","authors":"John V Heymach, David Harpole, Tetsuya Mitsudomi, Janis M Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T Le, Mike Aperghis, Gary J Doherty, Helen Mann, Tamer M Fouad, Martin Reck","doi":"10.1056/NEJMoa2304875","DOIUrl":"10.1056/NEJMoa2304875","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to improve long-term outcomes.</p><p><strong>Methods: </strong>We randomly assigned patients with resectable NSCLC (stage II to IIIB [N2 node stage] according to the eighth edition of the <i>AJCC Cancer Staging Manual</i>) to receive platinum-based chemotherapy plus durvalumab or placebo administered intravenously every 3 weeks for 4 cycles before surgery, followed by adjuvant durvalumab or placebo intravenously every 4 weeks for 12 cycles. Randomization was stratified according to disease stage (II or III) and programmed death ligand 1 (PD-L1) expression (≥1% or <1%). Primary end points were event-free survival (defined as the time to the earliest occurrence of progressive disease that precluded surgery or prevented completion of surgery, disease recurrence [assessed in a blinded fashion by independent central review], or death from any cause) and pathological complete response (evaluated centrally).</p><p><strong>Results: </strong>A total of 802 patients were randomly assigned to receive durvalumab (400 patients) or placebo (402 patients). The duration of event-free survival was significantly longer with durvalumab than with placebo; the stratified hazard ratio for disease progression, recurrence, or death was 0.68 (95% confidence interval [CI], 0.53 to 0.88; P = 0.004) at the first interim analysis. At the 12-month landmark analysis, event-free survival was observed in 73.4% of the patients who received durvalumab (95% CI, 67.9 to 78.1), as compared with 64.5% of the patients who received placebo (95% CI, 58.8 to 69.6). The incidence of pathological complete response was significantly greater with durvalumab than with placebo (17.2% vs. 4.3% at the final analysis; difference, 13.0 percentage points; 95% CI, 8.7 to 17.6; P<0.001 at interim analysis of data from 402 patients). Event-free survival and pathological complete response benefit were observed regardless of stage and PD-L1 expression. Adverse events of maximum grade 3 or 4 occurred in 42.4% of patients with durvalumab and in 43.2% with placebo. Data from 62 patients with documented <i>EGFR</i> or <i>ALK</i> alterations were excluded from the efficacy analyses in the modified intention-to-treat population.</p><p><strong>Conclusions: </strong>In patients with resectable NSCLC, perioperative durvalumab plus neoadjuvant chemotherapy was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone, with a safety profile that was consistent with the individual agents. (Funded by AstraZeneca; AEGEAN ClinicalTrials.gov number, NCT03800134.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1672-1684"},"PeriodicalIF":96.2,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cystic Fibrosis. 囊性纤维化。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 DOI: 10.1056/NEJMra2216474
Hartmut Grasemann, Felix Ratjen
{"title":"Cystic Fibrosis.","authors":"Hartmut Grasemann,&nbsp;Felix Ratjen","doi":"10.1056/NEJMra2216474","DOIUrl":"https://doi.org/10.1056/NEJMra2216474","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"389 18","pages":"1693-1707"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Bleeding Due to Small-Intestinal Angiodysplasias. 小肠血管发育不良出血的处理。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 DOI: 10.1056/NEJMe2310338
Loren Laine
{"title":"Management of Bleeding Due to Small-Intestinal Angiodysplasias.","authors":"Loren Laine","doi":"10.1056/NEJMe2310338","DOIUrl":"https://doi.org/10.1056/NEJMe2310338","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"389 18","pages":"1718-1720"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reducing Harm - Having Conversations about Firearm Storage. 减少伤害-谈论火器储存。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 DOI: 10.1056/NEJMp2310000
Ruth Abaya, Emmy Betz, Carl Kincaid, Sandra McKay, Chana A Sacks, Joseph Shahoud, Tahmir L Suters, Darren Taichman, Kendra Van de Water, Rayquan Williams
{"title":"Reducing Harm - Having Conversations about Firearm Storage.","authors":"Ruth Abaya,&nbsp;Emmy Betz,&nbsp;Carl Kincaid,&nbsp;Sandra McKay,&nbsp;Chana A Sacks,&nbsp;Joseph Shahoud,&nbsp;Tahmir L Suters,&nbsp;Darren Taichman,&nbsp;Kendra Van de Water,&nbsp;Rayquan Williams","doi":"10.1056/NEJMp2310000","DOIUrl":"https://doi.org/10.1056/NEJMp2310000","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"389 18","pages":"e36"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acquired Reactive Perforating Collagenosis. 获得性反应性穿孔性Collagenosis。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 DOI: 10.1056/NEJMicm2301877
Alvaro Prados-Carmona, Francisco J De la Torre Gomar
{"title":"Acquired Reactive Perforating Collagenosis.","authors":"Alvaro Prados-Carmona,&nbsp;Francisco J De la Torre Gomar","doi":"10.1056/NEJMicm2301877","DOIUrl":"https://doi.org/10.1056/NEJMicm2301877","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"389 18","pages":"e37"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete Hydatidiform Mole. 完整的Hydratidiform Mole。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 Epub Date: 2023-10-28 DOI: 10.1056/NEJMicm2304005
Yuanwei Liu, Peipei Hao
{"title":"Complete Hydatidiform Mole.","authors":"Yuanwei Liu,&nbsp;Peipei Hao","doi":"10.1056/NEJMicm2304005","DOIUrl":"10.1056/NEJMicm2304005","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1708"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimum-Staffing Rules for U.S. Nursing Homes - Opportunities and Challenges. 美国疗养院最低人员配置规则——机遇与挑战。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 Epub Date: 2023-10-28 DOI: 10.1056/NEJMp2310544
David C Grabowski, John R Bowblis
{"title":"Minimum-Staffing Rules for U.S. Nursing Homes - Opportunities and Challenges.","authors":"David C Grabowski,&nbsp;John R Bowblis","doi":"10.1056/NEJMp2310544","DOIUrl":"10.1056/NEJMp2310544","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1637-1640"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reforming Pharmacy Benefit Managers - A Review of Bipartisan Legislation. 改革药房福利管理者——两党立法回顾。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 Epub Date: 2023-10-28 DOI: 10.1056/NEJMp2309533
Christopher Cai, Benjamin N Rome
{"title":"Reforming Pharmacy Benefit Managers - A Review of Bipartisan Legislation.","authors":"Christopher Cai,&nbsp;Benjamin N Rome","doi":"10.1056/NEJMp2309533","DOIUrl":"10.1056/NEJMp2309533","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1640-1643"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corin and Left Atrial Cardiomyopathy, Hypertension, Arrhythmia, and Fibrosis. Corin与左心房心肌病、高血压、心律失常和纤维化。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2023-11-02 DOI: 10.1056/NEJMoa2301908
Hagit Baris Feldman, Chofit Chai Gadot, David Zahler, Adi Mory, Galit Aviram, Emil Elhanan, Gabi Shefer, Ilana Goldiner, Yam Amir, Alina Kurolap, Jacob N Ablin
{"title":"Corin and Left Atrial Cardiomyopathy, Hypertension, Arrhythmia, and Fibrosis.","authors":"Hagit Baris Feldman, Chofit Chai Gadot, David Zahler, Adi Mory, Galit Aviram, Emil Elhanan, Gabi Shefer, Ilana Goldiner, Yam Amir, Alina Kurolap, Jacob N Ablin","doi":"10.1056/NEJMoa2301908","DOIUrl":"10.1056/NEJMoa2301908","url":null,"abstract":"<p><p>Two siblings presented with cardiomyopathy, hypertension, arrhythmia, and fibrosis of the left atrium. Each had a homozygous null variant in <i>CORIN</i>, the gene encoding atrial natriuretic peptide (ANP)-converting enzyme. A plasma sample obtained from one of the siblings had no detectable levels of corin or N-terminal pro-ANP but had elevated levels of B-type natriuretic peptide (BNP) and one of the two protein markers of fibrosis that we tested. These and other findings support the hypothesis that BNP cannot fully compensate for a lack of activation of the ANP pathway and that corin is critical to normal ANP activity, left atrial function, and cardiovascular homeostasis.</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"389 18","pages":"1685-1692"},"PeriodicalIF":158.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信